Overview

Rilpivirine in Virologically Suppressed Adolescents

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
To describe the immunologic and virologic outcomes (HIV RNA, CD4) following switching from EFV to RPV in virologically suppressed adolescents
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mahidol University
Collaborator:
amfAR, The Foundation for AIDS Research
Treatments:
Rilpivirine